Purchase Order 75F40124P00405
Award Date 9/6/24
Potential Completion Date 8/31/25
Potential Value $47K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Folsom, CA 95630, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $396,400 firm-fixed-price definitive contract to Stemexpress, LLC (doing business as CGT Global), a woman-owned small business. The contract is for the delivery of COVID-19 positive serum samples. Stemexpress is a provider of human biological samples and specimen collection services for research and development in the life sciences. The company has previously supplied items to the Food and Drug...
- The U.S. Food and Drug Administration (FDA) awarded a Firm Fixed Price Purchase Order contract worth $94,003.45 to Charles River Laboratories Cell Solutions, Inc. for the provision of human primary CD34+ hematopoietic stem and progenitor cells. This contract supports the FDA's Center for Biologics Evaluation and Research (CBER), Division of Cell and Gene Therapy (DCGT) in conducting critical path research to develop and promote technology for the regulation of cellular and genetic...
- This federal contract award was granted to Stemcell Technologies Inc., a subsidiary of the Canadian biotechnology company Stemcell Technologies, by the Department of Health and Human Services (HHS). The contract, worth $24,908.80, is a firm fixed-price purchase order for the company to provide a range of specialized biological materials, laboratory supplies, scientific equipment, and proprietary products to support biomedical research initiatives across various HHS agencies, including the...
- This is a firm fixed-price purchase order awarded to Stemcell Technologies Inc., a foreign-owned, for-profit biotechnology company, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services. The contract is for the delivery of specialized cell culture kits, including the STEMDIFF MICROGLIA DIFFERENTIATION KIT, STEMDIFF MICROGLIA MATURATION KIT, and STEMDIFF HEMATOPOETIC...
- The Food and Drug Administration awarded a firm fixed-price purchase order to Charles River Laboratories Cell Solutions, Inc. for CD34+ stem/progenitor cells, with a ceiling value of $24,969.00. The contract, awarded on August 31, 2021, is scheduled for ultimate completion by March 12, 2026, and will be performed in Silver Spring, Maryland. No set-aside designation was applied to this award. This modification to the existing contract serves to de-obligate funds and close out the purchase...
- This is a firm-fixed-price purchase order awarded by the Department of Health and Human Services Food and Drug Administration to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of human induced pluripotent stem cell-derived cells. The $26,680 contract is to provide specialized cell cultures, including cardiomyocytes, neurons, astrocytes, and hepatocytes, to support the FDA's active research program. The award has no set-aside designation and is a sole-source award,...
- This federal contract award to Stemcell Technologies Inc., a Canadian biotechnology company, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a sub-agency of the U.S. Department of Health and Human Services (HHS). The $24,536.00 firm fixed-price purchase order is for the provision of the AMBIS 1787964 QUOTE Q-921198 item, which is described as the "EASY STEP NEGATIVE HUMAN CD4 KIT". The award does not have a small business set-aside designation. Stemcell...
- This is a $24,970.00 firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Stemcell Technologies Inc., a Canadian biotechnology company. The contract, which has no set-aside designation, is for the delivery of various cell culture research products, such as cell isolation kits, cell culture media, and automated cell separation instruments, to support biomedical...
- The U.S. Department of Health and Human Services (HHS) awarded a firm fixed-price Purchase Order contract worth $24,454.50 to Stemcell Technologies Inc., a Canadian biotechnology company, for the supply of specialized biological materials, laboratory supplies, scientific equipment, and proprietary products to support biomedical research initiatives across various HHS agencies. This contract, awarded on August 21, 2014, is not set aside for small businesses. Stemcell Technologies Inc. primarily...
- The U.S. Food and Drug Administration (FDA), through its National Center for Toxicological Research (NCTR), awarded a $24,895.00 firm-fixed-price purchase order to Fujifilm Cellular Dynamics, Inc. for the supply of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs), also referred to as "iCell Macrophages" from lot #106775. This sole-source procurement was conducted under the authority of FAR 13.106-1(b)(1) to support an approved scientific study (S00913) focused...